CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children

Therapeutic Drug Monitoring

Volumn 33, Issue 4, 2011, Pages 417-424

  Rakhmanina, Natella Y ^a,b,f   Neely, Michael N ^c   Van Schaik, Ron H N ^d   Gordish Dressman, Heather A ^a   Williams, Keetra D ^a   Soldin, Steven J ^e   Van Den Anker, John N ^a,b,c  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^e GEORGETOWN UNIVERSITY   (United States)

^f GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

ABCB1; Children; CYP3A5; HIV; Lopinavir; Ritonavir; SLCO1B1

Indexed keywords

CYTOCHROME P450 3A5; LOPINAVIR PLUS RITONAVIR; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER 1; VIRUS RNA;

ADOLESCENT; ADULT; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG CLEARANCE; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE; TREATMENT OUTCOME; VIRUS LOAD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYTOCHROME P-450 CYP3A; FEMALE; GENE FREQUENCY; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LOPINAVIR; MALE; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RITONAVIR;

EID: 80051792323     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318225384f     Document Type: Article

References (39)

1. Mouly SJ, Matheny C, Paine MF, et al. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther. 2005;78: 605-618. (Pubitemid 41773636)
2. Solas C, Simon N, Drogoul MP, et al. Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients. Br J Clin Pharmacol. 2007;64:353-362. (Pubitemid 47283866)
3. Weemhoff JL, von Moltke LL, Richert C, et al. Apparent mechanismbased inhibition of human CYP3A in-vitro by lopinavir. J Pharm Pharmacol. 2003;55:381-386. (Pubitemid 36410361)
4. Josephson F, Allqvist A, Janabi M, et al. CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clin Pharmacol Ther. 2007;81:708-712. (Pubitemid 46625107)
5. Woodahl EL, Yang Z, Bui T, et al. MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS. 2005;19:1617-1625. (Pubitemid 41502674)
6. Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (Pglycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75:13-33. (Pubitemid 38130115)
7. Hulgan T, Donahue JP, Hawkins C, et al. Implications of T-cell Pglycoprotein activity during HIV-1 infection and its therapy. J Acquir Immune Defic Syndr. 2003;34:119-126. (Pubitemid 37248908)
8. Chandler B, Almond L, Ford J, et al. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr. 2003;33:551-556. (Pubitemid 36975841)
9. Hartkoorn RC, Kwan WS, Shallcross V, et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics. 2010;20:112-120.
10. Kohlrausch FB, de Cassia Estrela R, Barroso PF, et al. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. Br J Clin Pharmacol. 2010;69:95-98.
11. Saitoh A, Singh KK, Powell CA, et al. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS. 2005;19:371-380. (Pubitemid 40446183)
12. Hesselink DA, van Schaik RH, Nauta J, et al. A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine. Pharmacogenomics. 2008;9:783-789.
13. Fanta S, Niemi M, Jonsson S, et al. Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet Genomics. 2008;18:77-90.
14. Volosov A, Alexander C, Ting L, et al. Simple rapid method for quantification of antiretrovirals by liquid chromatography-tandem massspectrometry. Clin Biochem. 2002;35:99-103. (Pubitemid 34442688)
15. Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002;54: 1271-1294. (Pubitemid 35284253)
16. Lee SJ, Usmani KA, Chanas B, et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics. 2003;13:461-472. (Pubitemid 37034588)
17. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383-391. (Pubitemid 32268418)
18. Ameyaw MM, Regateiro F, Li T, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 2001;11:217-221. (Pubitemid 32319871)
19. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70:189-199. (Pubitemid 32777772)
20. Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics. 2008;9:19-33. (Pubitemid 351560529)
21. Marzolini C, Tirona RG, Kim RB. Pharmacogenomics of the OATP and OAT families. Pharmacogenomics. 2004;5:273-282. (Pubitemid 38499966)
22. Estrela RC, Santoro AB, Barroso PF, et al. CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIVinfected subjects. Clin Pharmacol Ther. 2008;84:205-207.
23. Haas DW, Wu H, Li H, et al. MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J Acquir Immune Defic Syndr. 2003;34:295-298. (Pubitemid 37377363)
24. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002;359:30-36. (Pubitemid 34119193)
25. Ma Q, Brazeau D, Zingman BS, et al. Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics. 2007;8:227-235. (Pubitemid 46477734)
26. Winzer R, Langmann P, Zilly M, et al. No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur J Med Res. 2003;8:531-534.
27. Estrela Rde C, Ribeiro FS, Barroso PF, et al. ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy. Pharmacogenomics. 2009; 10:311-318.
28. Nasi M, Borghi V, Pinti M, et al. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS. 2003;17:1696-1698. (Pubitemid 36951692)
29. Brumme ZL, Dong WW, Chan KJ, et al. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS. 2003;17:201-208. (Pubitemid 36183046)
30. Ieiri I, Suwannakul S, Maeda K, et al. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther. 2007;82:541-547. (Pubitemid 47622520)
31. Ho RH, Choi L, Lee W, et al. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics. 2007;17:647-656. (Pubitemid 47057714)
32. Lau YY, Huang Y, Frassetto L, et al. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther. 2007;81:194-204. (Pubitemid 46174816)
33. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statininduced myopathy - a genomewide study. N Engl J Med. 2008;359: 789-799.
34. Ernest CS 2nd, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005;312: 583-591. (Pubitemid 40189555)
35. Chaillou S, Durant J, Garraffo R, et al. Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir. HIV Clin Trials. 2002;3: 493-501. (Pubitemid 36013558)
36. Donahue JP, Dowdy D, Ratnam KK, et al. Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy. Clin Pharmacol Ther. 2003;73:78-86. (Pubitemid 36158489)
37. Wyen C, Fuhr U, Frank D, et al. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther. 2008;84:75-82. (Pubitemid 351861487)
38. Rakhmanina N, van den Anker J, Baghdassarian A, et al. Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children. Antimicrob Agents Chemother. 2009;53: 2532-2538.
39. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157-1167. (Pubitemid 37122329)